Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field’s most promising and lucrative segments.

Read on to scan features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you assess the RA drugs market
Our report shows you revenue forecasts to 2026, sales results, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and R&D. Our 161 page report gives 67 tables and 65 charts to help your work.

With our study you can stay ahead in knowledge, benefiting your research, analyses, plans and decisions. There you find trends, innovations and opportunities for treating rheumatoid arthritis.

There is rising need worldwide for drugs treating arthritis. Our work helps you find markets, products and developments with most commercial promise.

The following sections show how you benefit from our new study.

Discover sales predictions for that overall world market and submarkets
Along with revenue prediction for the overall world market for treating RA, our work shows you forecasts to 2026 for two main submarkets:
• Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
• Non-biologics (other therapeutic molecules).

For the non-biologics submarket, you get three further revenue breakdowns to 2026:
• NSAIDs
• sDMARDs
• Others agents (grouped).

From 2016, how will the RA drugs market expand? Which parts will most prosper? For anti-rheumatic medicines, our report helps you identify sales potentials and find opportunities.

Our investigation also discusses what stimulates and restrains business. There you explore dynamics of that industry, also seeing what products can achieve the most success.

With our analysis you discover how high sales can go, to 2026, finding drugs and years with highest predicted revenues and growth. You also assess competition, exploring trends, challenges and opportunities.

Our analysis also divides its overall world RA revenue forecast into geographical segments.

What sales and growth potentials for leading countries?
In developed and developing countries – especially India and China – there remain many opportunities for expanded selling of drugs to treat rheumatoid arthritis. Our study shows you individual revenue forecasts to 2026 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

That way you discover progress and outlooks. You assess the industry’s future – hear about developments and find what they mean.

Our analysis shows revenue growth will occur in established pharma markets and in emerging countries. In particular, product launches from 2016 to 2026 will change anti-rheumatic drug prescribing and the commercial landscape. See what is possible.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new RA drugs? Our study shows you developmental trends for these agents and others:
• IL-6 inhibitors
• JAK inhibitors
• BTK inhibitors.

In our work you assess innovations, hearing about developments and finding their meaning. For large companies and specialty pharma firms there exist many opportunities in treating rheumatoid arthritis. Assess those firms’ prospects.

Our study explains, also discussing forces affecting those companies and their market.

Prospects for arthritic R&D are encouraging, and from 2016 there will arise opportunities, including product launches. Our work shows you technological, clinical and commercial possibilities, helping you stay ahead in knowledge.

6 main ways Rheumatoid Arthritis (RA) Drugs Market 2016-2026 helps your work
In particular our investigation gives you the following knowledge to help your research, plans, decisions and presentations:
• Revenues to 2026 for the overall rheumatoid arthritis drugs market and for 5 world-level submarkets – discover sales and growth potentials
• Revenues to 2026 for 11 leading products – find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2026 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China – see national sales potentials, finding the best regions for revenues and sales growth
• R&D for treating rheumatoid arthritis – investigate technologies and progress, assessing medical and commercial possibilities
• Discussions of leading companies, including profiles of 8 leading players – hear about strategies, capabilities, results and outlooks
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages.

9. Conclusions
9.1 Global Market for RA Drugs Will Contract After 2018
9.2 Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By 10%
9.3 Enbrel Will Overtake Humira as the Leading Drug
9.4 US Will Remain the Dominant Market
9.5 Trends in the RA Drugs Market